SU1480766A3 - Способ получени кристаллического торасемида - Google Patents
Способ получени кристаллического торасемида Download PDFInfo
- Publication number
- SU1480766A3 SU1480766A3 SU864027953A SU4027953A SU1480766A3 SU 1480766 A3 SU1480766 A3 SU 1480766A3 SU 864027953 A SU864027953 A SU 864027953A SU 4027953 A SU4027953 A SU 4027953A SU 1480766 A3 SU1480766 A3 SU 1480766A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- modification
- torasemide
- space group
- chemically pure
- admixture
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims abstract description 44
- 238000012986 modification Methods 0.000 claims abstract description 44
- 230000004048 modification Effects 0.000 claims abstract description 43
- 229960005461 torasemide Drugs 0.000 claims abstract description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 3
- 230000003197 catalytic effect Effects 0.000 claims abstract 3
- 238000001816 cooling Methods 0.000 claims abstract 3
- 239000012670 alkaline solution Substances 0.000 claims abstract 2
- 230000007935 neutral effect Effects 0.000 claims abstract 2
- 238000000926 separation method Methods 0.000 claims abstract 2
- 239000000243 solution Substances 0.000 claims abstract 2
- 238000003860 storage Methods 0.000 claims description 6
- 229940088623 biologically active substance Drugs 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims 4
- 230000008018 melting Effects 0.000 claims 4
- 230000001882 diuretic effect Effects 0.000 abstract description 2
- 239000002934 diuretic Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 238000005029 sieve analysis Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LV930452A LV5240A3 (lv) | 1985-08-17 | 1993-06-01 | Kristaliska torasemida iegusanas panemiens |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853529529 DE3529529A1 (de) | 1985-08-17 | 1985-08-17 | Verfahren zur herstellung einer stabilen modifikation von torasemid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1480766A3 true SU1480766A3 (ru) | 1989-05-15 |
Family
ID=6278766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU864027953A SU1480766A3 (ru) | 1985-08-17 | 1986-08-15 | Способ получени кристаллического торасемида |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US4743693A (enExample) |
| EP (1) | EP0212537B1 (enExample) |
| JP (2) | JPS6245576A (enExample) |
| KR (1) | KR930009818B1 (enExample) |
| AU (1) | AU573454B2 (enExample) |
| CA (1) | CA1307277C (enExample) |
| CS (2) | CS259891B2 (enExample) |
| DD (1) | DD259858A5 (enExample) |
| DE (2) | DE3529529A1 (enExample) |
| DK (1) | DK162518C (enExample) |
| ES (1) | ES2001522A6 (enExample) |
| FI (1) | FI82189C (enExample) |
| GR (1) | GR862139B (enExample) |
| HK (1) | HK59994A (enExample) |
| HU (1) | HU195778B (enExample) |
| IE (1) | IE59237B1 (enExample) |
| IL (1) | IL79672A (enExample) |
| LT (1) | LT3596B (enExample) |
| NO (1) | NO170079C (enExample) |
| NZ (1) | NZ217172A (enExample) |
| PL (1) | PL146086B1 (enExample) |
| PT (1) | PT83186B (enExample) |
| SU (1) | SU1480766A3 (enExample) |
| UA (1) | UA7080A1 (enExample) |
| ZA (1) | ZA866151B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2126388C1 (ru) * | 1993-03-03 | 1999-02-20 | Берингер Маннхайм ГмбХ | 4-аминопиридины и фармацевтическая композиция |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3623620A1 (de) * | 1986-07-12 | 1988-01-21 | Boehringer Mannheim Gmbh | Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung |
| US5166162A (en) * | 1990-03-02 | 1992-11-24 | Adir Et Compagnie | Pyridylsulfonylurea and pyridylsulfonylthiourea compounds |
| JP3586471B2 (ja) * | 1991-06-25 | 2004-11-10 | 三菱ウェルファーマ株式会社 | トラセミド含有医薬組成物 |
| HRP980532B1 (en) * | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
| US6166045A (en) | 1998-06-02 | 2000-12-26 | Roche Diagnostics Gmbh | Torasemide of modification III |
| US5914336A (en) | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| US20030026835A1 (en) * | 1999-02-15 | 2003-02-06 | Sumitomo Pharmaceuticals Company Limited | Tablets disintegrating rapidly in the oral cavity |
| HRP20020120A2 (en) | 1999-08-11 | 2003-10-31 | Teva Pharma | Torsemide polymorphs |
| SK11632003A3 (sk) | 2000-02-17 | 2004-04-06 | Teva Pharmaceutical Industries Ltd. | Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu |
| HRP20000162B1 (en) * | 2000-03-20 | 2004-06-30 | Pliva D D | Amorphous torasemide modification |
| CA2403382A1 (en) | 2000-03-20 | 2001-09-27 | Teva Pharmaceutical Industries Ltd. | Novel processes for preparing torsemide intermediate |
| HRP20000765A2 (en) * | 2000-11-10 | 2002-06-30 | Pliva D D | Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release |
| US20030022921A1 (en) * | 2001-02-21 | 2003-01-30 | Minutza Leibovici | Stable pharmaceutical formulation comprising torsemide modification II |
| IN192178B (enExample) * | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
| EP2316469A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
| ITMI20020639A1 (it) * | 2002-03-27 | 2003-09-29 | Cosma S P A | Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea |
| HRP20020603B1 (en) * | 2002-07-19 | 2008-11-30 | Pliva D.D. | New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide |
| DE03789888T1 (de) * | 2002-11-18 | 2005-08-18 | Teva Pharmaceutical Industries Ltd. | Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol |
| JP2006516574A (ja) * | 2003-02-05 | 2006-07-06 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール安定化方法 |
| ES2244324B1 (es) * | 2004-03-25 | 2006-11-16 | Ferrer Internacional, S.A. | Composiciones diureticas de liberacion prolongada. |
| AT500576B1 (de) * | 2004-07-28 | 2006-11-15 | Sanochemia Pharmazeutika Ag | Verfahren zur reindarstellung von kristallformen von torsemid |
| US10178893B1 (en) * | 2013-06-14 | 2019-01-15 | Scott Bradley Baker | Shoe |
| FR3018688A1 (fr) * | 2014-03-19 | 2015-09-25 | Virbac | Utilisation de torasemide a faible dose dans une composition veterinaire |
| US12048677B2 (en) | 2014-12-12 | 2024-07-30 | Ceva Sante Animale | Compositions and uses thereof for the treatment of heart failure in domestic animals |
| EP3031471A1 (en) * | 2014-12-12 | 2016-06-15 | Ceva Sante Animale | Veterinary composition for the treatment of pulmonary edema associated with heart failure in domestic animals |
| DK3173075T3 (en) * | 2015-11-27 | 2019-01-21 | Accupharma Spolka Z Ograniczona Odpowiedzialnoscia | PHARMACEUTICAL COMBINATION PREPARATION OF ACE INHIBITOR AND LOOPDIURETIC |
| CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30633A (en) * | 1860-11-13 | Improvement in fire-escapes | ||
| GB1477664A (en) * | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| GB1593609A (en) * | 1978-01-31 | 1981-07-22 | Christiaens Sa A | Pyridine sulfonamides |
| LU85193A1 (fr) * | 1984-01-31 | 1985-09-12 | Christiaens Sa A | Nouveaux derives de la 4-phenylaminopyridine,leur utilisation et leur preparation |
-
1985
- 1985-08-17 DE DE19853529529 patent/DE3529529A1/de active Granted
-
1986
- 1986-08-10 IL IL79672A patent/IL79672A/xx not_active IP Right Cessation
- 1986-08-11 AU AU61055/86A patent/AU573454B2/en not_active Expired
- 1986-08-11 CA CA000515676A patent/CA1307277C/en not_active Expired - Lifetime
- 1986-08-11 CS CS865945A patent/CS259891B2/cs not_active IP Right Cessation
- 1986-08-11 US US06/895,355 patent/US4743693A/en not_active Ceased
- 1986-08-12 NZ NZ217172A patent/NZ217172A/xx unknown
- 1986-08-12 PT PT83186A patent/PT83186B/pt unknown
- 1986-08-12 DE DE8686111118T patent/DE3667970D1/de not_active Expired - Lifetime
- 1986-08-12 EP EP86111118A patent/EP0212537B1/de not_active Expired - Lifetime
- 1986-08-13 DK DK385586A patent/DK162518C/da not_active IP Right Cessation
- 1986-08-13 IE IE217986A patent/IE59237B1/en not_active IP Right Cessation
- 1986-08-14 DD DD86293655A patent/DD259858A5/de not_active IP Right Cessation
- 1986-08-14 ES ES8601131A patent/ES2001522A6/es not_active Expired
- 1986-08-14 KR KR1019860006689A patent/KR930009818B1/ko not_active Expired - Lifetime
- 1986-08-14 GR GR862139A patent/GR862139B/el unknown
- 1986-08-15 SU SU864027953A patent/SU1480766A3/ru active
- 1986-08-15 NO NO863305A patent/NO170079C/no not_active IP Right Cessation
- 1986-08-15 FI FI863305A patent/FI82189C/fi not_active IP Right Cessation
- 1986-08-15 PL PL1986261052A patent/PL146086B1/pl unknown
- 1986-08-15 HU HU863598A patent/HU195778B/hu unknown
- 1986-08-15 ZA ZA866151A patent/ZA866151B/xx unknown
- 1986-08-15 UA UA4027953A patent/UA7080A1/uk unknown
- 1986-08-18 JP JP61191789A patent/JPS6245576A/ja active Granted
-
1987
- 1987-10-20 US US07/111,439 patent/US4822807A/en not_active Ceased
-
1989
- 1989-10-27 JP JP1278800A patent/JPH0643400B2/ja not_active Expired - Lifetime
-
1991
- 1991-12-31 CS CS914199A patent/CS419991A3/cs unknown
-
1992
- 1992-12-03 US US07/985,053 patent/USRE34580E/en not_active Expired - Lifetime
-
1993
- 1993-04-08 US US08/043,631 patent/USRE34672E/en not_active Expired - Lifetime
- 1993-08-27 LT LTIP898A patent/LT3596B/lt not_active IP Right Cessation
-
1994
- 1994-06-23 HK HK59994A patent/HK59994A/xx not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| Structure d une Seconde Variete de la Torasemide. - Acta crystallographica, 1978, 2659-2662. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2126388C1 (ru) * | 1993-03-03 | 1999-02-20 | Берингер Маннхайм ГмбХ | 4-аминопиридины и фармацевтическая композиция |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1480766A3 (ru) | Способ получени кристаллического торасемида | |
| RU2066324C1 (ru) | Кристаллический дигидрат азитромицина и способ его получения | |
| JPH02167286A (ja) | クラバラン酸の塩、その製法及び用途 | |
| CH657134A5 (de) | Amorphe form eines cefuroximesters, verfahren zu ihrer herstellung und diese enthaltende zusammensetzung. | |
| NO320047B1 (no) | Sammensetning for oral administrering | |
| BG51042A3 (bg) | Метод за получаване на безводна,кристална натриева сол на 5-хлор- 3(2-теноил)-2-оксиндол-1-карбоксамид | |
| JPH029885A (ja) | セファロスポリン塩および注射可能な組成物 | |
| JPH0643429B2 (ja) | 高度に結晶性のナトリウムセフオペラゾンの製法 | |
| US2474758A (en) | Complex salts of streptothricin | |
| US6703410B1 (en) | Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide | |
| JP2628368B2 (ja) | 高純度ラクチュロース粉末の製造法ならびにラクチュロースを含むビフイズス菌製剤の製造法 | |
| JPH05222056A (ja) | セファロスポリン抗生物質の結晶性形状 | |
| HRP940506A2 (en) | Crystals of an antimicrobal compound | |
| CA1293738C (en) | Production of stable sodium acetylsalicylate | |
| US3692766A (en) | Calcium lactulosate | |
| DK167319B1 (da) | Stabilt hydrat af et penicillinderivat og fremgangsmaade til fremstilling deraf | |
| JP3755908B2 (ja) | セファロスポリン化合物の晶析法 | |
| US4124636A (en) | Method of preparing monopotassium L-malate and its monohydrate | |
| RU2137775C1 (ru) | Способ выделения натриевой соли оксациллина | |
| KR880001235B1 (ko) | 결정성 무수 소듐 19-데옥시아글리콘 디아네마이신의 제조 방법 | |
| JPH0157115B2 (enExample) | ||
| EP0461520A2 (en) | Oxetanocin G anhydride crystals and process for producing the same | |
| KR20070034080A (ko) | 1,24(ｓ)-디히드록시 비타민 ｄ2의 결정형 | |
| US4293560A (en) | Talampicillin 2-methoxyphenoxyacetate and pharmaceutical compositions containing it | |
| JPS6032616B2 (ja) | 高い貯蔵安定性の無水アセチルサリチル酸ナトリウム |